HETEROCOMPOUND Russian patent published in 2011 - IPC C07D413/04 C07D413/14 C07D417/04 C07D471/04 A61K31/4245 A61K31/4353 A61K31/4709 A61P37/02 A61P37/06 

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula

or pharmaceutically acceptable salt thereof, where symbols assume the following values; ring denotes

or , X denotes a single bond, -CH₂-, -NR³-, -O-, -S-, R¹ denotes a halogen; phenyl; pyridyl; (C₃-C₈)cycloalkyl; or (C₁-C₆) alkyl or (C₂-C₆) alkenyl, each of which can contain a halogen, -CONH₂, phenyl or (C₃-C₈)cycloalkyl as a substitute, R² denotes CN, -O-(C₁-C₆)alkyl, -C(=O)H, halogen; or (C₁-C₆)alkyl, which can be substituted with a halogen or -OH, R³ can form morpholino or 1-pyrrolidinyl together with R¹ and nitrogen, and when X denotes a single bond, R¹ and R² can jointly form a 5-member ring and additionally contain -(C₁-C₆)alkyl as a substitute, R⁴ denotes the following ring: , , , , , , , , , , or , where any one of the bonds in the ring is linked to an oxazole ring, R⁵ denotes -H, (C₁-C₆)alkyl, which can be substituted by not less than one group selected from: -C(=O)NR^XR^Y, -NHR^X and -OR^X- (C₂-C₆)alkenyl-; -C(=O)H; -C(=O)NR^XR^Y, R^X and R^Y can be identical or different and denote -H; or (C₁-C₆)alkyl. The invention also relates to a pharmaceutical composition based on said compounds, having SlP₁ agonist activity.

EFFECT: compounds and compositions can be used in medicine for preventing and treating rejection during organ transplant, bone marrow or tissue transplant and autoimmune diseases.

16 cl, 84 tbl, 198 ex